JOHNSON & JOHNSON is 400.6x more valuable than MBX Biosciences, Inc. by market capitalization ($573.98 B vs $1.43 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MBX | JNJ |
|---|---|---|
| Market cap | $1.43 B | $573.98 B |
| US-listed rank | #2364 | #20 |
| Revenue (latest FY) | - | $94.19B |
| Net income (latest FY) | -$87.00M | $26.80B |
| Net margin | - | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 198 | 984 |
JOHNSON & JOHNSON is 400.6x more valuable than MBX Biosciences, Inc. by market capitalization ($573.98 B vs $1.43 B).
Full pages: MBX Biosciences, Inc. and JOHNSON & JOHNSON, or browse the full rankings.